You are here

Article Text

Article menu
Download PDFPDF
Lung alert
Interferon gamma-1b does not improve survival for patients with idiopathic pulmonary fibrosis
  1. Alex Mackay
  1. Homerton University Hospital, Department of Respiratory Medicine, London, UK
  1. Correspondence to Dr Alex Mackay, Specialist Registrar, Homerton University Hospital, Department of Respiratory Medicine, London, UK; malexmackay{at}hotmail.com

https://doi.org/10.1136/thx.2009.132886

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Idiopathic pulmonary fibrosis (IPF) is characterised by an insidious decline in pulmonary function, progressive worsening symptoms and death, with a median survival of 2–5 years from diagnosis. A methodologically limited meta-analysis has suggested that interferon γ-1b (IFNγ-1b) might improve survival.

    To test this hypothesis, the INSPIRE study group conducted a double-blind trial, randomising 826 patients with IPF to receive IFNγ-1b …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; not externally peer reviewed.